BRAF and melanoma: Besides, studies have shown that loss of STAG2 or STAG3 inhibits CCCTC-binding factor (CTCF) mediated dual specificity phosphatase 6 (DUSP6) expression, leading to a significant decrease in DUSP6 protein levels and ultimately reactivation of MEK-ERK signaling in BRAF-inhibitor treated melanoma cells (99).